← Leaderboards
Kevin O Saunders
Duke University
$14,270,231
Attributed
$14,270,231
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $7.7M · FY2009–25$10M$7.5M$5M$2.5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$33,226,779 · 7
By mechanism
U19$25,653,687 · 5
R01$7,509,014 · 1
F31$64,078 · 1
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- Kouros Owzar$6,468,635
- Cliburn C Chan$13,214,865
- Barton F Haynes$531,570,874
- John H Sampson$43,413,436
- Michael Barry Kastan$65,974,699
Others in their field
Top investigators on “Hiv-1”
- Barton F Haynes · Duke University$476,288,740
- Lawrence Corey · Fred Hutchinson Cancer Center$445,419,385
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$294,186,693
- Constance Ann Benson · University Of California, San Diego$272,046,180
- Peter B. Gilbert · Fred Hutchinson Cancer Center$173,010,936
- Dan H. Barouch · Fred Hutchinson Cancer Center$166,542,502
Research focus
Hiv-1VaccinesAntibodiesB-LymphocytesAntigensNanoparticleDesignNeutralizing AntibodyProductionCell LineageInfectionHiv-1 VaccineMutationMacaca MulattaMolecular ConformationMacacaSerumPhenotypeMonoclonal AntibodiesAntibody ResponseInnovationImmunogenicAffinityProteins
Grant awards (24)
Conjugate nanoparticle platform development for HIV-1 envelope immunogens$4,623,440
U19 · FY2025 · AI · contact PI
Project 1. Optimization and in vivo evaluation of HIV-1 Env trimer sortase A-conjugated nanoparticles$1,541,147
U19 · FY2025 · AI · contact PI
Administrative Core$1,541,147
U19 · FY2025 · AI · contact PI
Conjugate nanoparticle platform development for HIV-1 envelope immunogens$4,794,780
U19 · FY2024 · AI · contact PI
Project 1. Optimization and in vivo evaluation of HIV-1 Env trimer sortase A-conjugated nanoparticles$826,400
U19 · FY2024 · AI · contact PI
HIV-1 vaccine-elicited antibodies target envelope glycans$733,115
R01 · FY2024 · AI · contact PI
Administrative Core$285,964
U19 · FY2024 · AI · contact PI
Conjugate nanoparticle platform development for HIV-1 envelope immunogens$4,818,748
U19 · FY2023 · AI · contact PI
Project 1. Optimization and in vivo evaluation of HIV-1 Env trimer sortase A-conjugated nanoparticles$834,191
U19 · FY2023 · AI · contact PI
HIV-1 vaccine-elicited antibodies target envelope glycans$747,507
R01 · FY2023 · AI · contact PI
Administrative Core$259,820
U19 · FY2023 · AI · contact PI
Conjugate nanoparticle platform development for HIV-1 envelope immunogens$4,719,580
U19 · FY2022 · AI · contact PI
Project 1. Optimization and in vivo evaluation of HIV-1 Env trimer sortase A-conjugated nanoparticles$1,131,614
U19 · FY2022 · AI · contact PI
HIV-1 vaccine-elicited antibodies target envelope glycans$774,421
R01 · FY2022 · AI · contact PI
Administrative Core$276,856
U19 · FY2022 · AI · contact PI
HIV-1 vaccine-elicited antibodies target envelope glycans$789,761
R01 · FY2021 · AI · contact PI
HIV-1 vaccine-elicited antibodies target envelope glycans$817,205
R01 · FY2020 · AI · contact PI
HIV-1 vaccine-elicited antibodies target envelope glycans$700,558
R01 · FY2019 · AI · contact PI
HIV-1 vaccine-elicited antibodies target envelope glycans$643,994
R01 · FY2018 · AI · contact PI
HIV-1 vaccine-elicited antibodies target envelope glycans$759,765
R01 · FY2017 · AI · contact PI
HIV-1 vaccine-elicited antibodies target envelope glycans$780,235
R01 · FY2016 · AI · contact PI
HIV-1 vaccine-elicited antibodies target envelope glycans$762,453
R01 · FY2015 · AI · contact PI
Elucidation of the Mechanisms of CD8+ T Cell Noncytolytic Antiviral Response$22,902
F31 · FY2010 · AI · contact PI
Elucidation of the Mechanisms of CD8+ T Cell Noncytolytic Antiviral Response$41,176
F31 · FY2009 · AI · contact PI